Journal: Investigative Ophthalmology & Visual Science

Article Title: Goblet Cell Differentiation Potential in Human Corneal Limbal Epithelial Progenitor Cells In Vitro

doi: 10.1167/iovs.61.12.27

Figure Lengend Snippet: FGFR, Fibroblast Growth Factor Receptor

Article Snippet: The following Abs were used: mouse anti-cytokeratin-3/2p monoclonal antibody (mAb; AE-5, 1:100; Santa Cruz Biotechnology, Inc, Dallas, TX, USA), mouse anti-human cytokeratin-4 mAb (6B10, 1:300; Abcam, Cambridge, UK), rabbit monoclonal [EP1599Y] anti-human cytokeratin 4 (1:200, Abcam), mouse anti-human cytokeratin-7 mAb (RCK105, 1:10000; Millipore, Billerica, MA, USA), mouse anti-human cytokeratin-13 mAb (1:20; American Research Products, Inc., Palos Verdes, CA, USA), mouse anti-human cytokeratin-12 mAb (N-16; 1:500; Santa Cruz Biotechnology), rabbit anti-cytokeratin 12/K12 mAb (1:200, EPR17882, Abcam), rabbit anti-human MUC5AC polyclonal Ab (H-160, 1:100, Santa Cruz Biotechnology), anti-FGFR1 mAb (1:200, 133105; R&D Systems, Minneapolis, MN, USA), anti-human FGFR2 (blocking) mAb (1:200, 98725; R&D Systems), anti-FGFR3 mAb (1:200, 135334; R&D Systems), anti-FGFR4 mAb (1:200, 137114; R&D Systems), and anti-FGFR1 blocking mAb (VBS1; Chemicon, Temecula, CA, USA).

Techniques:

Journal: Investigative Ophthalmology & Visual Science

Article Title: Goblet Cell Differentiation Potential in Human Corneal Limbal Epithelial Progenitor Cells In Vitro

doi: 10.1167/iovs.61.12.27

Figure Lengend Snippet: FGF receptor expression and effect of FGF receptor blockade in colonies derived from adherent single cells. ( A ) FGFR1 and FGFR2, but not FGFR3 and FGFR4, are detected in the adherent colonies by RT-PCR. ( B ) FGFR1 and FGFR2 expression is detected by Western blotting. ( C ) Effect of FGF receptor blockade was tested in colonies derived from adherent single cells. PAS-positive colony number in the anti-FGFR1 monoclonal antibody group significantly decreases as compared with that in the control Ig group. Treatment with an anti-FGFR2 blocking mAb does not affect the number of colony. ( D ) Colony with amorphous material and epithelium is observed with control IgG. ( E ) Anti-FGFR1 mAb suppresses the proliferation of both goblet-like cell and epithelium. Similar results were obtained with repeated three experiments. M, size markers; S, sample; P, positive control; N, negative control, N.S., not significant.

Article Snippet: The following Abs were used: mouse anti-cytokeratin-3/2p monoclonal antibody (mAb; AE-5, 1:100; Santa Cruz Biotechnology, Inc, Dallas, TX, USA), mouse anti-human cytokeratin-4 mAb (6B10, 1:300; Abcam, Cambridge, UK), rabbit monoclonal [EP1599Y] anti-human cytokeratin 4 (1:200, Abcam), mouse anti-human cytokeratin-7 mAb (RCK105, 1:10000; Millipore, Billerica, MA, USA), mouse anti-human cytokeratin-13 mAb (1:20; American Research Products, Inc., Palos Verdes, CA, USA), mouse anti-human cytokeratin-12 mAb (N-16; 1:500; Santa Cruz Biotechnology), rabbit anti-cytokeratin 12/K12 mAb (1:200, EPR17882, Abcam), rabbit anti-human MUC5AC polyclonal Ab (H-160, 1:100, Santa Cruz Biotechnology), anti-FGFR1 mAb (1:200, 133105; R&D Systems, Minneapolis, MN, USA), anti-human FGFR2 (blocking) mAb (1:200, 98725; R&D Systems), anti-FGFR3 mAb (1:200, 135334; R&D Systems), anti-FGFR4 mAb (1:200, 137114; R&D Systems), and anti-FGFR1 blocking mAb (VBS1; Chemicon, Temecula, CA, USA).

Techniques: Expressing, Derivative Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot, Control, Blocking Assay, Positive Control, Negative Control

Journal: Translational Lung Cancer Research

Article Title: TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent TP53 mutations and FGFR pathway dysregulation

doi: 10.21037/tlcr-2025-690

Figure Lengend Snippet: Kaplan-Meier curve showing OS probability among p40/TTF-1 double expressor NSCLC cases, comparing patients with FGFR1 overexpression and/or amplification (FGFR1alt) to those without these alterations (FGFR1wt). The P value was calculated using the log-rank test. FGFR, fibroblast growth factor receptor; NSCLC, non-small cell lung cancer; OS, overall survival; wt, wild-type.

Article Snippet: Primary antibodies used for FGFR detection were: FGFR1 (NB100-2080, Novus Biologicals, USA; pH 6.0, 1:100), FGFR2 (H00002263-M01, Abnova, Taiwan; pH 6.0, 1:600), FGFR3 (B-9: sc-13121, Santa Cruz Biotechnology; pH 6.0, 1:50), and FGFR4 (M00769-2, Boster Bio, USA; pH 6.0, 1:500).

Techniques: Over Expression, Amplification

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Identification of genes discriminating FGFR1 amplification from FGFR1 neutral in the discovery cohort [ie, the preoperative letrozole (POL)-Z1031 cohort]. A: The REMARK diagram shows 25 FGFR1-amplified estrogen receptor–positive (ER+) tumors were chosen to be compared against 39 FGFR1 neutral and chromosome 8 diploid ER+ tumors for genes discriminative of FGFR1 amplification. B: Firestorm analysis. The segmented array comparative genomic hybridization (aCGH) copy number signals from the circular binary segmentation algorithm (in log2 ratio, y axis) were plotted against chromosome 8 genome locations (x axis). The top panel shows a FGFR1 firestorm amplified tumor example, and the bottom panel shows a FGFR1 neutral and chromosome 8 diploid tumor example. C: Heat map of the mRNA gene expression levels (in red/green color scheme) of the nine genes (at row). Overexpression of the genes corresponds well to the FGFR1-amplified cases among the 64 samples (at column), as determined by the firestorm analysis (indicated in the top image bar as truth: AMP in pink for amplification and NonAMP in blue for nonamplification).

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Amplification, Hybridization, Gene Expression, Over Expression

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Validation of individual genes and development/evaluation of multigene signatures in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort. A: The REMARK diagram; 1508 estrogen receptor–positive (ER+) METABRIC samples were used for FGFR1 amplification analyses. B: Disease-specific survival (DSS) Kaplan-Meier (KM) curves of true FGFR1 amplification status, as determined by single-nucleotide polymorphism (SNP) array copy number analysis stratified by ER status, demonstrated that FGFR1 amplification is prognostic in ER+ tumors but not in ER- tumors. In parentheses are total number of events/total number of samples with valid survival and FGFR1 amplification data. The hazard ratios (HRs) with associated 95% CIs and the log-rank test P values (P) are reported. C: Individual receiver operating characteristic (ROC) curve confirms the discriminative ability of each individual gene for FGFR1 amplification. The solid black point indicates the optimal cutoff point on each ROC curve. The legend shows area under the ROC curve (AUC), sensitivity, and specificity corresponding to the optimal cutoff. D: Overlaid KM curves for DSS indicate that each of the four composite signatures is prognostic and tracks the true nonamplified curve well. KM curves of amplification statuses, as determined by each of the four multigene signatures from 10-fold cross-validations (red dashed curves: upper/lower red curves for nonamplified/amplified patients, respectively), were overlaid by gold standard FGFR1 amplification status, as determined by SNP array copy number analysis (black solid curves, upper/lower curves for nonamplified/amplified patients, respectively), and amplification status, as determined by both a signature and the true status (green dotted curves, upper/lower curve for nonamplified cases determined by both/amplified cases determined by both, respectively). The HRs with associated 95% CIs and the log-rank test P values (P) are reported. The signature Call-FGFR1-amp based on the optimal AUC (optAUC) algorithm was carried forward locked down for validation. EMP, empirical method; Logistic, logistic regression method; NB, naïve Bayes method.

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Biomarker Discovery, Amplification

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Validation of FGFR1 amplification calls by Call-FGFR1-amp in the Strategic Partnering to Evaluate Cancer Signatures (SPECS) cohort. A: The REMARK diagram; 47 estrogen receptor–positive (ER+) SPECS samples were analyzed for FGFR1 amplification analyses. B: Kaplan-Meier (KM) curves by true FGFR1 amplification status, as determined by fluorescent in situ hybridization (FISH) for relapse-free survival (RFS), overall survival (OS), and disease-specific survival (DSS), show prognostic trends. Indicated in the legend are the total number of events/total number of patients corresponding to the amplified and nonamplified patients in the parenthesis, hazard ratios (HRs), and 95% CIs and log-rank test P values (P). C: Heat map of the nine selected genes (at row) shows concordance between the genes' overexpression, the amplification statuses called by Call-FGFR1-amp, and the FGFR1 FISH amplification statuses of the 47 ER+ tumors (at column), indicated in the top image bar by pred (for Call-FGFR1-amp) and truth (for FISH), respectively. AMP in pink/purple for amplification and NonAMP in blue for nonamplification. White bars are for cases with nonreadable FISH results. D: Overlaid KM curves exhibit close tracking of Call-FGFR1-amp for FGFR1 FISH, showing similar prognostic effects. KM curves for RFS, OS, and DSS by FGFR1 amplification based on Call-FGFR1-amp (Call-FGFR1-amp: red dashed curves, upper/lower red curves corresponding to nonamplified versus amplified patients, as determined by Call-FGFR1-amp, respectively), overlaid with curves by the FISH gold standard (FGFR1: black solid curves, upper/lower curves corresponding to nonamplified versus amplified patients, as determined by FISH, respectively) and FGFR1 status, as determined by both Call-FGFR1-amp and FISH (FGFR1 and Call-FGFR1-amp: green dotted curves, the upper green dotted curve representing patients who were FGFR1 FISH amplified and called so by Call-FGFR1-amp versus the lower green dotted curves representing the remaining patients who were called nonamplified by both or had inconsistent calls between FISH and Call-FGFR1-amp). The HRs with 95% CIs and log-rank test P values (P) were indicated in the legend.

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Biomarker Discovery, Amplification, In Situ Hybridization, Over Expression

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Validation of FGFR1 amplification calls by Call-FGFR1-amp in the University of British Columbia (UBC)–tamoxifen (TAM) cohort. A: The REMARK diagram; 651 estrogen receptor–positive (ER+) UBC-TAM samples were analyzed for FGFR1 amplification analyses. B: Kaplan-Meier (KM) curves by true FGFR1 amplification status, as determined by fluorescent in situ hybridization (FISH), show prognostic effects for disease-specific survival (DSS) and relapse-free survival (RFS). C: Heat map of the nine selected genes (at row) shows concordance between the genes' overexpression, the amplification statuses called by Call-FGFR1-amp, and the FGFR1 FISH amplification statuses of the 651 ER+ tumors (at column), indicated in the top image bar by pred (for Call-FGFR1-amp) and truth (for FISH), respectively. AMP in pink/purple for amplification and NonAMP in blue for nonamplification. White bars are for cases with nonreadable FISH results. D: Overlaid KM curves exhibit close tracking of Call-FGFR1-amp for FGFR1 FISH, showing similar prognostic effects. KM curves for DSS and RFS by FGFR1 amplification based on Call-FGFR1-amp (Call-FGFR1-amp: red dashed curves, upper/lower red curves corresponding to nonamplified versus amplified patients, as determined by Call-FGFR1-amp, respectively), overlaid with curves by the FISH gold standard (FGFR1: black solid curves, upper/lower curves corresponding to nonamplified versus amplified patients, as determined by FISH, respectively) and FGFR1 status, as determined by both Call-FGFR1-amp and FISH (FGFR1 and Call-FGFR1-amp: green dotted curves, the upper green dotted curve representing patients who were FGFR1 FISH amplified and called so by Call-FGFR1-amp versus the lower green dotted curves representing the remaining patients who were called nonamplified by both or had inconsistent calls between FISH and Call-FGFR1-amp). The hazard ratios (HRs) with 95% CIs and log-rank test P values (P) were indicated in the legend. QC, quality control.

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Biomarker Discovery, Amplification, In Situ Hybridization, Over Expression, Control

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Selection of the Candidate Genes in the Discovery Cohort (POL-Z1031)

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Selection

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Contingency Table of FGFR1 Amplification Calls as Determined by Call-FGFR1-amp against the FISH Gold Standards in the SPECS Cohort

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Amplification

Journal: The Journal of Molecular Diagnostics : JMD

Article Title: An mRNA Gene Expression–Based Signature to Identify FGFR1 -Amplified Estrogen Receptor–Positive Breast Tumors

doi: 10.1016/j.jmoldx.2016.09.007

Figure Lengend Snippet: Contingency Table of FGFR1 Amplification Calls as Determined by Call- FGFR1 -Amp against the FISH Gold Standards in the UBC-TAM Cohort

Article Snippet: FGFR1 (8p12)/CEN8q FISH probes (Abnova, Taipei, Taiwan) were codenatured with the tissues at 73°C for 5 minutes and hybridized at 37°C for 16 to 18 hours.

Techniques: Amplification

Journal: PLoS ONE

Article Title: An Integrative Genomic and Transcriptomic Analysis Reveals Potential Targets Associated with Cell Proliferation in Uterine Leiomyomas

doi: 10.1371/journal.pone.0057901

Figure Lengend Snippet: Seventy-five modulators obtained from integrative analysis.

Article Snippet: The FGFR1 (GeneTex, San Antonio, TX, USA; clone polyclonal; dilution 1∶400) and IGFBP5 (Santa Cruz, Santa Cruz, CA, USA; clone C18; dilution 1∶100) antibodies were incubated for 30 minutes at room temperature.

Techniques:

Journal: PLoS ONE

Article Title: An Integrative Genomic and Transcriptomic Analysis Reveals Potential Targets Associated with Cell Proliferation in Uterine Leiomyomas

doi: 10.1371/journal.pone.0057901

Figure Lengend Snippet: Cell proliferation and extracellular matrix deposition process with high similarity observed in ULs. FGFR1 and IGFBP5 were selected as potential molecular markers in ULs treatment.

Article Snippet: The FGFR1 (GeneTex, San Antonio, TX, USA; clone polyclonal; dilution 1∶400) and IGFBP5 (Santa Cruz, Santa Cruz, CA, USA; clone C18; dilution 1∶100) antibodies were incubated for 30 minutes at room temperature.

Techniques:

Journal: PLoS ONE

Article Title: An Integrative Genomic and Transcriptomic Analysis Reveals Potential Targets Associated with Cell Proliferation in Uterine Leiomyomas

doi: 10.1371/journal.pone.0057901

Figure Lengend Snippet: (A) Boxplot illustrating MM (normal) and ULs (tumour) normalised to obtain relative expression values for all samples evaluated by RT-qPCR. P = paired t test significance. ** P = 0.006; *** P = 0.0002; Immunostaining frequency for the (B) FGFR1 and (C) IGFBP5 proteins. The P values (Fisheŕs test) were obtained based on the comparison of the MM and ULs immunostaining results.

Article Snippet: The FGFR1 (GeneTex, San Antonio, TX, USA; clone polyclonal; dilution 1∶400) and IGFBP5 (Santa Cruz, Santa Cruz, CA, USA; clone C18; dilution 1∶100) antibodies were incubated for 30 minutes at room temperature.

Techniques: Expressing, Quantitative RT-PCR, Immunostaining, Comparison

Journal: PLoS ONE

Article Title: An Integrative Genomic and Transcriptomic Analysis Reveals Potential Targets Associated with Cell Proliferation in Uterine Leiomyomas

doi: 10.1371/journal.pone.0057901

Figure Lengend Snippet: (A) FGFR1-adjacent normal myometrium showing FGFR1 low level expression (score 1); (B) and (C) FGFR1 cytoplasmic positive expression in uterine leiomyoma tissue (scores 2 and 3/intensity, respectively); (D) adjacent normal myometrium showing IGFBP5 negative expression (score 0); (E) and (F) IGFBP5 cytoplasmic positive expression in uterine leiomyoma tissue (scores 2 and 3/intensity, respectively) (200×).

Article Snippet: The FGFR1 (GeneTex, San Antonio, TX, USA; clone polyclonal; dilution 1∶400) and IGFBP5 (Santa Cruz, Santa Cruz, CA, USA; clone C18; dilution 1∶100) antibodies were incubated for 30 minutes at room temperature.

Techniques: Expressing